Form 4: ProMIS Neurosciences Chief Medical Officer Granted Stock Options

ProMIS Neurosciences' Chief Medical Officer, Larry Douglas Altstiel, was granted options to purchase 175,000 common shares.

Summary

• Larry Douglas Altstiel, the Chief Medical Officer of ProMIS Neurosciences Inc., was granted options to purchase 175,000 common shares.
• The options were granted on November 18, 2024, at an exercise price of $1 per share.
• 25% of the options will vest on November 18, 2025, and the remaining options will vest ratably over the following 36 months.
• The options expire on November 18, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative issues.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the Chief Medical Officer.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, aligning their interests with shareholders.
• The vesting schedule of 25% after one year and the remainder over 36 months is a typical vesting structure for stock options.

Stakeholder Impact

• The stock option grant may positively impact shareholder value by incentivizing the Chief Medical Officer to improve company performance.

Key Dates

Keywords

stock options, insider trading, executive compensation, vesting, ProMIS Neurosciences, PMN, Chief Medical Officer